Targeted Therapy in HER2-Positive Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|39|5|295-302

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.5, 2016-04, pp. : 295-302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted Therapy of HER2-Negative Breast Cancer

Oncology Research and Treatment, Vol. 39, Iss. 3, 2016-02 ,pp. : 118-121

Karger

Access to resources Recommend Favorite

Neoadjuvant Therapy for HER2-positive Breast Cancer

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 81-92

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer

Oncology Research and Treatment, Vol. 33, Iss. 8-9, 2010-07 ,pp. : 420-421

Karger

Access to resources Recommend Favorite

Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 93-100

Bentham Science Publishers

Access to resources Recommend Favorite

Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?

By Santini Daniele Vincenzi Bruno Tonini Giuseppe

Women's Health, Vol. 2, Iss. 1, 2006-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite